+ Watch PFE
on My Watchlist
A research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra.
Expiring patents are already priced in so that will have no effect on their stock price. They have a history of creating blockbuster drugs and there are more to come as they currently have 118 drugs in the pipeline. 60 of those are in phase 2 or 3. Last year they surpassed $1 billion in annual revenue in both China and Brazil for the first time in the company’s history. These are two of the largest emerging pharmaceutical markets globally so continued growth is expected. This is a dependable, low risk company, with growth potential and a great dividend. OUTPERFORM!!!
What about the rumor of pfizer buy out of Nutra Pharma Corp (NPHC.OB) $5 to $7 per share. Sound cheap to me. Many great patents and applications.
I haven't heard about that, I will have to look into it
I continue to be high on PFE. I picked them to outperform back when they were at $17 and they have steadily increased since that time. I researched this company more than any other company I have ever researched, and I couldn't find any reason not to invest. They will continue to climb and as soon as the come out with their next blockbuster drug, they will climb even quicker. Also, with the good dividend and low risk, it is an extremely solid investement.
It was a great call and this one is not done yet.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions